Prelude Therapeutics (PRLD) Accumulated Expenses (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Accumulated Expenses data on file, last reported at $5.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 47.47% year-over-year to $5.9 million; the trailing twelve-month figure through Mar 2026 stood at $5.9 million (down 47.47% YoY), and the FY2025 full-year result was $12.5 million, up 38.92% from the prior year.
• Accumulated Expenses slipped to $5.9 million in Q1 2026, from $12.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $15.8 million in Q4 2023 to a low of $3.0 million in Q1 2022.
• A 5-year average of $8.5 million and a median of $7.6 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses jumped 269.92% in 2023 and sank 67.47% in 2024, its largest moves.
• Tracing PRLD's Accumulated Expenses over 5 years: stood at $13.1 million in 2022, then advanced by 20.43% to $15.8 million in 2023, then sank by 42.78% to $9.0 million in 2024, then jumped by 38.92% to $12.5 million in 2025, then tumbled by 52.62% to $5.9 million in 2026.
• Business Quant data shows PRLD's Accumulated Expenses at $5.9 million in Q1 2026, $12.5 million in Q4 2025, and $6.5 million in Q3 2025.